Cel-Sci

Cel-Sci

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases. The company was founded in 1983 by Maximilian de Clara, in Vienna, Virginia, United States.

The company looks to deal with clinical phases of head and neck cancer. Their theory is to boost the immune system before turning to options such as surgery, radiation, and chemotherapy.

COVID-19

The company has began developing an immunotherapy solution for the potential to treat patients with COVID-19. The outbreak of the coronavirus has prompted Cel-Sci to provide their peptide technology LEAPS which stimulates protective cell mediated T-cell responses and reduce viral loads. The technology can be used to build peptides that exhibit both antiviral and anti-inflammatory properties. LEAPS is designed to target the infectious virus, and also start the appropriate protective response to it.

LEAPS is a peptide-based medicine that can help reduce tissue damage caused by lung infections, which is a mortality issue for elderly patients.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Cel-Sci funding round, August 2009
4,400,000
August 20, 2009
Alpha Capital
Ramius
CEL SCI CORP funding round, July 2018
78,000
July 2018
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Eyal Talor

CSO

Geert R. Kersten

CEO

Maximilian de Clara

President, Director

Further reading

Title
Author
Link
Type
Date

Cel Sci - Cel Sci Corp

Web

Coronavirus outbreak: Top coronavirus drugs and vaccines in development

Web

March 11, 2020

Coronavirus outbreak: Top coronavirus drugs and vaccines in development

Web

March 11, 2020

US biotech CEL-SCI Corporation has announced that it is developing an immunotherapy with the potential...

The Pharma Letter

Web

US biotech CEL-SCI Corporation has announced that it is developing an immunotherapy with the potential...

The Pharma Letter

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

CEL-SCI

Geert Kersten

Vienna, Virginia, United States

Therapeutics and pharmaceuticals

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.